WTF?

Quote

Anonymous

Guest
With the acquisition of Cadiokine's hospital product and Spectracef, Factive and Zyflo CR either having generic competition or an expired patent. Is anyone else concerned about what is going to happen to the office based sales force? Plus they rose the price of Zyflo CR which is typically done when a company anticipates that they will not be receiving revenue in the near future From this angle it seems like Corp. might not need us for to much longer. The Cardiokine product is scheduled for approval Q1 2013.

Sorry if I took the jelly outta your doughnut but you/we gotta look out for things like this.
 






























All Crtx does is raise the cost of meds! That's been the "strategic direction" for the past 3 years... If the reps can't sell enough just keep raising the price! Then we have to deal w drs and pharmacies asking us why our drugs cost $700 a script - its such a joke....
 




































Top Bottom
Back
Quote